Close

Genetic Technologies (GTG) Signs Multi-Year US Distribution Agreement for COVID Risk Test

Go back to Genetic Technologies (GTG) Signs Multi-Year US Distribution Agreement for COVID Risk Test

Genetic Technologies Signs Multi-Year US Distribution Agreement for COVID Risk Test

March 4, 2021 7:00 AM EST

MELBOURNE, Australia, March 04, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, Company, GTG), a diversified Genomics and AI-driven preventative health business is pleased to announce a co-exclusive production and distribution rights and license agreement (Agreement) with US-based Infinity BiologiX LLC (IBX), a leading central laboratory providing sample collection and processing, storage, analytical services, and scientific and technical support, for the production, distribution and sale of the Companys COVID-19 Serious Disease Risk (sdr) Test (COVID-19 Risk Test) in the United States.

Highlights

Initial three-year co-exclusive licence agreement between IBX and GTG for the production,... More